Novartis AG - Research and Development

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Research-and-Development" stands at 10.88 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2024.

Novartis AG's third quarter result of 2.94 Billion USD for the item "Research and Development" represents an increase of 7.96 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 2.94 Billion USD for the item "Research and Development" represents an increase of 23.08 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 10.88 Billion USD for the item "Research and Development" represents an increase of 5.35 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 11.61 percent compared to the value the year prior.
The 1 year change in percent is 11.61.
The 3 year change in percent is 11.36.
The 5 year change in percent is 14.52.
The 10 year change in percent is 20.88.

The Serie's long term average value is 9.47 Billion United States Dollars. It's latest available value, on 09/30/2025, is 14.87 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2018, to it's latest available value, on 09/30/2025, is +25.71%.
The Serie's change in percent from it's maximum value, on 12/31/2023, to it's latest available value, on 09/30/2025, is -4.33%.